Plain-English translation of NCT07063875 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining two medications — tebentafusp and IL-2 (Proleukin) — can work better together than tebentafusp alone for patients with metastatic uveal melanoma (a rare eye cancer that has spread). Tebentafusp works by training your immune system to recognize and attack cancer cells, and this study wants to see if adding IL-2, which boosts your immune system further, can help overcome cases where the cancer stops responding to the first medication alone.
Metastatic uveal melanoma is a very serious cancer with few treatment options and poor survival rates. While this medication has shown promise, some patients' cancers eventually stop responding to it. This trial exists to explore whether combining it with an immune-boosting drug might help patients whose cancer is no longer controlled by the first treatment alone.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive both medications as part of your treatment. The trial is small (enrolling only 8 people), and you would work closely with the research team at St Vincent's Hospital in Sydney to monitor how well the combination works and how your body responds. Expect regular visits for blood tests, scans, and check-ins to track your progress and any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Australia